ArticleInternational journal of molecular sciences2026
Label-Free Detection of Molecular Signatures in Heart Failure with Preserved Ejection Fraction Using Raman Micro-Spectroscopy.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous syndrome characterized by delayed diagnosis and limited therapeutic options, contributing to poor clinical outcomes. In the present study, we investigated the applicability of Raman micro-spectroscopy (RmS) as a label-free, rapid, and cost-effective approach for identifying molecular signatures associated with HFpEF and enabling reliable disease classification. RmS was applied to evaluate disease-related biochemical alterations in cardiac and renal tissues obtained from a clinically relevant HFpEF model (ZSF1 rat). Furthermore, the effects of three pharmacological interventions were analyzed and classified (five experimental groups-36 animals in total), highlighting organ-specific therapeutic responses. We developed a spectroscopic data analysis strategy in which second-derivative Raman spectral features serve as quantitative inputs to a supervised classification model, enabling micro-spectroscopic discrimination of HFpEF versus control tissues and achieving a classification accuracy of 92% (sensitivity 93% and specificity 91%) based on the protein-to-tryptophan ratio in cardiac tissue, while minimizing the need for extensive data preprocessing. The spectroscopic markers used in this study were derived from prior multivariate discovery analyses and are evaluated here within a validation and translational classification framework. Collectively, these findings support the integration of RmS into molecular and translational research settings and suggest its potential utility for improving HFpEF diagnosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.